For over a decade the folate receptor has been intensively investigated as a means for
tumor-specific delivery of a broad range of experimental therapies including several …

Over the last 25+ years, the folate receptor (FR) has emerged as an attractive tumor
biomarker with the potential to be exploited for therapeutic purposes. Increasing evidence …

Conventional cancer treatment modalities have several limitations including lack of sufficient
efficacy, serious untoward toxicity, as well as innate and acquired drug resistance. In …

Increasing evidence suggests that the folate receptor (FR) can be exploited for therapeutic
applications. This endocytosing protein is well known to functionally mediate the cellular …

The folate receptor (FR) is a confirmed tumor-associated antigen that binds folate and folate–
drug conjugates with very high affinity and shuttles these bound molecules inside cells via …

Folate receptor α (FRα) came into focus as an anticancer target many decades after the
successful development of drugs targeting intracellular folate metabolism, such as …

Targeted delivery via selective cellular markers can potentially increase the efficacy and
reduce the toxicity of therapeutic agents. The folate receptor (FR) has two glycosyl …

Introduction: Folate receptor− α (FR− α) has been established as a membrane marker for
ovarian cancer. In addition, it is frequently overexpressed in other major types of epithelial …

The membrane-bound folate receptor (FR) is overexpressed on a wide range of human
cancers, such as those originating in ovary, lung, breast, endometrium, kidney and brain …

The folate receptor alpha (FR) is expressed in a variety of gynecological cancer types. It has
been widely used for tumor targeting with folic acid conjugates of diagnostic and therapeutic …